RNA241220P43000
- 8.50
- +1.25+17.24%
Avidity Biosciences Newsroom
RBC Initiates Avidity Biosciences at Outperform, Speculative Risk With $67 Price Target
Avidity Biosciences Analyst Ratings
RBC Capital Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $67
Avidity Biosciences Price Target Maintained With a $65.00/Share by Chardan Capital
Avidity Biosciences Is Maintained at Buy by Chardan Capital
TD Cowen Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $78
TD Cowen Reaffirms Their Buy Rating on Avidity Biosciences (RNA)
A Quick Look at Today's Ratings for Avidity Biosciences(RNA.US), With a Forecast Between $51 to $65
Avidity Biosciences (RNA) Gets a Buy From Barclays
Avidity Biosciences Analyst Ratings
Buy Rating Affirmed for Avidity Biosciences Amid Precision Cardiology Advancements
Barclays Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $63
A Quick Look at Today's Ratings for Avidity Biosciences(RNA.US), With a Forecast Between $60 to $78
Analysts Conflicted on These Healthcare Names: Molina Healthcare (MOH), Avidity Biosciences (RNA) and MoonLake Immunotherapeutics (MLTX)
A Quick Look at Today's Ratings for Avidity Biosciences(RNA.US), With a Forecast Between $51 to $75
Avidity Biosciences Is Maintained at Buy by Chardan Capital
Avidity Biosciences Analyst Ratings
TD Cowen Maintains Avidity Biosciences(RNA.US) With Buy Rating, Raises Target Price to $78
TD Cowen Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $56
A Quick Look at Today's Ratings for Avidity Biosciences(RNA.US), With a Forecast Between $56 to $75